HARD TO TREAT DISEASES INC. 
By 3rd Q financials exemption used to Curb Oversold - Naked Short Sellers
The company brings attention to its filing Dated
The issuer is of the opinion that it has met the threshold of the "Adequate Disclosure" requirement.
Moreover the issuer brings attention to the Pink Sheets weekly report. The weekly report can be found at this link:
Go to www.minamargroup.net
Click on MARKET REPORT
SELECT HTDS
This is a pdf file that a user can download to their local drive or open it in a browser.
The issuer brings attention to the TOP RIGHT HAND CORNER of that report.
The issuer is ranked internally as CURRENT ISSUER and publically as Caveat Emptor.
The issuer is of the opinion that the short sellers and "oversold" require the issuer to be in the TOP 2 tier ranking namely LIMITED INFORMATION or CURRENT INFORMATION in order for the short sellers to continue borrowing stocks from each other and shorting its security.
The issuer being a non reporting SEC company will utilize its exemption status and not file its Q3 statements with Pink Sheets in an effort to thwart the short seller's efforts, in an effort to force a short squeeze.
The issuer continues its audit and its aspirations of up listing to OTCBB. The auditor is currently engaged on completing HTDS' 2007-2008 financials. Audited statements are one of the requirements the company must obtain to meet the OTCBB listing threshold. HTDS management does not foresee any issues in meeting the audit requirements. HTDS management has a prearranged OTCBB vehicle already ready formulated and capitalized for its operating subsidiaries and the soon to be announced merger up list to OTCBB.
In other company news, the issuer has received some very positive feedback on its MMR Vaccine and the Chinese SFDA's decision. Details will be released shortly. In addition its Serbia Bio Chem subsidiary competition for the best technological innovation will be reported shortly as well.
The issuer also brings attention to its SEC filing on Pink Sheets regarding Naked Short selling
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com
SOURCE Hard to Treat Diseases
